Radi olabeled amino acids (AAs) have long been recognized as useful tumor imaging agents, and several tracers, including L-11 C-methionine and O-(2-18 F-fluoroethyl)-L-tyrosine ( 18 F-FET), have been used clinically, particularly for brain tumors. These tracers target the increased rates of amino acid transport present in many types of tumor cells. In the brain, these tracers provide better tumor visualization than the most widely used PET tracer for oncology, 18 F-FDG, and contrast-enhanced MR imaging alone (1) (2) (3) (4) (5) . There are also data suggesting that 18 F-FET PET can differentiate low-grade from high-grade gliomas and can more accurately evaluate tumor response to therapy earlier in the course of treatment than MR imaging (3, (6) (7) (8) (9) (10) . There has been a growing appreciation that radiolabeled AAs targeting different AA transport systems have distinct imaging properties and may provide unique biologic information relevant to prognosis and therapy (11) (12) (13) (14) .
The bulk of work performed with radiolabeled AAs has focused on substrates for system L AA transport, which preferentially transports AAs with bulky neutral side chains like L-leucine, L-tyrosine, and L-phenylalanine through an energy-independent exchange mechanism. To date, more than 20 AA transporter systems have been identified with varying specificities for substrates, sodium and pH dependences, and tissue-expression patterns. Major transport systems recognized as relevant to tumor imaging include system L, system A, and system ASC (14) (15) (16) .
Recently, there has been growing interest in other AA transport systems, including xCT, glutamine, and cationic AA transporters (17) (18) (19) (20) . Our group recently reported a novel 18 This tracer is a structural analog of histidine and showed promising tumor imaging properties in the rat 9 L gliosarcoma model, which has been used for the preclinical evaluation of several radiolabeled AAs (21) (22) (23) (24) . The in vitro uptake of this compound was mediated, in part, by cationic AA transport, and 18 F-AFETP represents a lead compound for a new class of radiolabeled AA for tumor imaging. The transport was stereospecific, and the (R)-enantiomer of AFETP demonstrated lower tumor uptake and tumorto-normal-tissue ratios (22) .
Although relatively unexplored, cationic AA transport is an attractive target for oncologic imaging. Specific cationic AA transporters are upregulated in human cancers including cervical and colorectal (25, 26) . The cationic AA transporter CAT-1 is active at the blood-brain barrier (BBB), possibly allowing visualization of the nonenhancing regions of gliomas (27) . Cationic AA transporters recognize L-lysine, L-arginine, and L-histidine as substrates, and both L-lysine and L-histidine are essential AAs that cannot be synthesized by human cells. L-arginine is conditionally essential in rapidly dividing cells and in cells that lack the enzyme arginosuccinate synthase (ASS), which is absent in a range of human cancers and is a target for therapy using arginine deiminase (28, 29) . Additionally, L-arginine plays important roles in polyamine synthesis and nitric oxide metabolism, which are relevant to tumor cell proliferation and angiogenesis, respectively. The roles of cationic AA transport and metabolism for predicting prognosis, selecting therapies, and monitoring response to therapy are not currently defined in large part because of the lack of well-characterized molecular imaging agents for purpose.
To further assess the utility of 18 F-AFETP for tumor imaging, this tracer was evaluated in the mouse delayed brain tumor (DBT) model, a syngeneic murine model of glioblastoma (30) . The tumor imaging properties of 18 F-AFETP were evaluated in mice with intracranial DBTs through biodistribution and small-animal PET/CT studies. Additionally, the tumor and brain uptake of 18 F-AFETP was compared with those of 18 F-FDG and 18 F-FET ( Fig. 1 ) through small-animal PET studies because these tracers are clinically relevant and used for brain tumor imaging in patients.
MATERIALS AND METHODS

Radiosynthesis
18 F-FDG was produced by the Washington University Cyclotron Facility. 18 F-AFETP and 18 F-FET were radiosynthesized using literature methods with minor modifications (22, 31) . 18 F-fluoride was produced from 18 O-H 2 O using an RDS 111 cyclotron (CTI) through the 18 O(p,n) 18 F reaction. 18 F-AFETP (3) was prepared in a 2-step reaction starting from 2-18 F-fluoroethyl azide and tert-butyl ester of N-Boc-(S)-propargyl glycine (1) based on the previously published procedure with minor modifications, as depicted in Figure 2 (22) . The crude 18 F-labeled protected intermediate 2 was injected directly onto the Agilent Zorbax C18 semipreparative high-performance liquid chromatography (HPLC) column (250 · 10 mm, 10 mm) without isolation through a reversed-phase cartridge (Waters, Inc.), as in the original report. A larger volume of 1.0 M aqueous hydrochloric acid (1.0 mL) was used for the microwave-assisted deprotection of the intermediate to eliminate the intermittent presence of a minor radiochemical impurity in the final product. For cell uptake assays, the acidic solution was evaporated to dryness by heating to 105°C with nitrogen gas flow, and 18 F-AFETP was dissolved in sterile water to avoid the presence of sodium ions. For the rodent studies, the acidic solution was neutralized through the addition of 1.0 M aqueous sodium bicarbonate (1.0 mL), passed through a 0.22-mm nylon filter, and then diluted in 0.9% sodium chloride for injection. The radiochemical purity and specific activity of 18 F-AFETP were confirmed using radiometric thin-layer chromatography and HPLC analyses including the coinjection of nonradioactive reference compound. 18 F-FET was performed with the commercially available Eckert and Ziegler Modular Lab using the method described by Zuhayra et al. with a 1-bromo-2-18 F-fluoroethane for O-alkylation of the L-tyrosine (32) .
Cell Uptake Assays
Cell uptake assays were performed using the cluster-tray method as reported in the literature (22, 33) . Mouse DBT glioma cells were cultured at 1 · 10 5 per 24 well (Corning) for 48 h in a 5% CO 2 atmosphere in 10% fetal bovine serum-Dulbecco modified Eagle medium. Two buffer conditions, with and without sodium, were used for the assays. The phosphate-buffered saline solution contained 105 mM sodium chloride, 3.8 mM potassium chloride, 1.2 mM potassium bicarbonate, 25 mM sodium phosphate dibasic, 0.5 mM calcium chloride dihydrate, 1.2 mM magnesium sulfate, and 5.6 mM D-glucose. The sodium-free, phosphate-buffered choline solution was identical to the phosphate-buffered saline solution except that choline chloride and choline phosphate dibasic were substituted for sodium chloride and sodium phosphate dibasic, respectively.
The following inhibitors were used for the cell uptake assays: N-methyl-a-aminoisobutyric acid (MeAIB, 10 mM), a mixture of L-alanine/L-serine/L-cysteine (ASC, 3.3 mM of each AA), (R,S)-(endo,exo)-2-aminobicyclo(2,2,1)-heptane-2-carboxylic acid (BCH, 10 mM), L-arginine (10 mM), L-lysine (10 mM), L-histidine (10 mM), and a mixture of L-arginine/L-lysine/L-histidine (RKH, 3.3 mM of each AA). The control conditions contained 10 mM sucrose to maintain consistent osmolality. All assays were performed in quadruplicate at pH 7.40, as described previously (22, 33) . The uptake data were expressed as percentage of uptake relative to control, normalized to total protein content in each well. The data were analyzed with 1-way ANOVA with Tukey multiple pairwise comparisons using GraphPad Prism software (GraphPad Software), with P values of 0.05 or less considered statistically significant.
DBT Model
All animal experiments were conducted according to protocols approved by the Animal Studies Committee at the Washington University School of Medicine.
The DBT model was chosen because it exhibits many features of human glioblastomas. These tumor cells are positive for glial fibrillary acidic protein and are highly motile. Orthotopic DBTs in mouse brain have been previously characterized in studies comparing MR imaging, bioluminescence, and histologic measurements of tumor volume (30) . The DBT cells (1 · 10 4 cells suspended in 8 mL) were implanted in the right mid cerebrum of male BALB/c mice (20-25 g ) at 2 mm posterior to the bregma, as described previously (34) . The DBT cell line constitutively expresses the enzyme luciferase. The presence of viable DBTs was confirmed through bioluminescence imaging, and animals were sorted on the basis of tumor size and location into matched cohorts before imaging studies, as described previously (30, 35) . 
Biodistribution Studies with 18 F-AFETP
Biodistribution studies were performed using male BALB/c mice with intracranial DBTs at 13 d after implantation. Mice were anesthetized with 1% isoflurane-oxygen, and approximately 1.1 MBq of 18 F-AFETP was administered via tail vein injection. The animals were euthanized in groups of 3 or 4 at 5, 30, and 60 min after injection. The tumors, organs, and tissues of interest were dissected and weighed, and the amounts of radioactivity were measured using an automated Beckman g-8000 well counter. Additionally, radioactive standards from the dosages were counted. The concentrations of radioactivity in the tumors and the normal organs and tissues normalized as percentage injected dose per gram (%ID/g) of radioactivity in the tumors and the normal organs and tissues as well as ratios of tumor to normal organ and tumor to normal tissue were calculated. The data for blood, brain, muscle, and tumor were analyzed for each time point with 1-way ANOVA with Tukey multiple pairwise comparisons using GraphPad Prism software.
MR Imaging
MR imaging experiments were performed on 4 mice with intracranial DBTs at day 12 after implantation. Data were collected on a dedicated small-animal MR scanner built around an Oxford Instruments 4.7-T magnet, using an Agilent/Varian DirectDrive console, high-performance Agilent/Magnex gradients, and International Electric Co. gradient power supplies. Mice were anesthetized with isoflurane-O 2 (2%-3% [v/v]) and maintained on isoflurane-O 2 (1% [v/v]) throughout the experiments. Animal body temperature was maintained at 37°C with warm, circulating water. Mice were injected intraperitoneally with 500 mL of MultiHance (Bracco Diagnostics, Inc.) contrast agent, diluted 1:10 in sterile saline, 15 min before being placed in the magnet. T2-weighted, spin-echo MR images were collected with the following parameters: repetition time, 2 s; echo time, 0.03 s; field of view, 1.5 · 1.5 cm 2 ; slice thickness, 0.5 mm; number of averages, 4; and data matrix, 128 · 128.
Small-Animal PET/CT Imaging
Male BALB/c mice (n 5 4) with intracranial DBTs were anesthetized with 1% isoflurane-O 2 . The mice then underwent dynamic small-animal PET imaging from 0 to 60 min after intravenous tail injection of 7.4-11.1 MBq of 18 F-AFETP on day 14 and 11.1 MBq of 18 F-FDG on day 15 after tumor implantation, using Inveon and microPET Focus 220 systems (Siemens Medical Solutions Inc.). The animals were fasted overnight before the 18 F-FDG studies and allowed to feed ad libitum before the 18 F-AFETP and 18 F-FET studies. The animals were maintained at 37°C during the study using a warming lamp. CT images were also acquired with the Inveon system. A separate cohort of male BALB/c mice (n 5 4) with intracranial DBTs underwent the same imaging protocol after the administration of 7.4-11.1 MBq of 18 F-FET. At the conclusion of the imaging studies, the animals were euthanized, and their brains were fixed for 24-48 h in 4% paraformaldehyde for histologic analysis with hematoxylin and eosin staining to verify the presence and location of tumor.
The small-animal PET data were analyzed by manually drawing 3-dimensional regions of interest (ROIs) over the tumor identified on the PET studies, with correlation to MR imaging and histology to confirm the tumor location. ROIs for normal brain were drawn over the cerebral hemisphere contralateral to the tumor. The ROIs for the tumors ranged from 13 to 30 mm 3 , and comparable ROIs were drawn over the contralateral normal brain. The uptake data were expressed as average standardized uptake values (SUVs) for each ROI. The average of the SUVs in brain and tumor, as well as the average of the tumor-tobrain ratios at 50-60 min after injection for 18 F-AFETP, 18 F-FDG, and 18 F-FET, were compared with 1-way ANOVA with Tukey multiple pairwise comparisons using GraphPad Prism software.
RESULTS
Radiochemistry
18 F-AFETP was produced in 58% 6 4% (n 5 6) decay-corrected yield in a total synthesis and formulation time of approximately 2.5 h, using the modified procedure. As in the original report, the enantiomeric excess, as assessed by analytic chiral HPLC, was greater than 98%, with the undesired (R)-enantiomer below the limits of detection. The overall radiochemical purity was greater than 99%, and the specific activity of the 18 F-AFETP was approximately 44 GBq/mmol (n 5 6), decay-corrected to the end of bombardment. For 18 F-FET, the final radiotracer was purified using HLB reversedphase cartridges (Waters, Inc.) in an average radiochemical yield of 27%, with a greater than 98% radiochemical purity and greater than 37 GBq/mmol specific activity (n 5 4).
Cell Uptake Assays
The results of the in vitro cell uptake assays are displayed in Figure  3 . In the presence of 10 mM L-histidine or 10 mM L-lysine, 87% and 77% of 18 F-AFETP uptake by DBT cells, respectively, was blocked. In the assay buffer containing choline ions, 18 F-(S)-AFETP demonstrated an inhibition of 62%. In the ASC condition, approximately 50%-58% of uptake was inhibited. The variability observed between the ASC conditions in different assays (50% 6 8% and 42% 6 4%) is within experimental error for this type of assay. A minor, but statistically significant, inhibition of uptake was observed with the system A inhibitor MeAIB and the system L inhibitor BCH.
Biodistribution Studies with 18 F-AFETP
The results of biodistribution studies with 18 F-AFETP in male BALB/c mice are shown in Table 1 . The tumor uptake after injection was rapid, with 4.4 6 1.1 %ID/g at 5 min. There was persistent retention of activity in the tumor at the 30-min time point (4.9 6 1.2 %ID/g), which decreased slightly to 2.5 6 1.0 %ID/g at 60 min. The %ID/g of 18 F-AFETP was significantly higher than normal brain and muscle at all time points and higher than blood at 30 and 60 min after injection (P , 0.001). The resulting tumor-to-brain ratios at the 5-, 30-, and 60-min time points were 17:1, 14:1, and 11:1, respectively. The tumor-to-normal-tissue ratios at 30 and 60 min after injection were greater than 2:1 for the blood, bone fat, liver, muscle, and large intestine.
Small-Animal PET Studies in Mice with DBTs
Representative small-animal PET and MR images obtained with 18 F-AFETP, 18 F-FDG, and 18 F-FET are presented in Figure 4 , and representative time-activity curves are shown in Figure 5 as average SUVs and tumor-to-brain ratios over time. The PET studies revealed a significant difference in uptake and kinetics in DBT and normal brain for all 3 tracers. Relatively high uptake occurred in the DBTs at both early (7.5-12.5 min) and late time points (47.5-57.5 min), with 18 F-FDG significantly greater than 18 F-FET greater than 18 F-AFETP as shown in Figure 6 . These 18 F-labeled tracers differed substantially in their amount of uptake in normal brain, with 18 F-FDG significantly greater than 18 F-FET greater than 18 F-AFETP. The uptake of 18 F-FDG in brain tumor was only slightly above that in normal brain at the conclusion of the 60-min study. The average tumor-to-brain ratios for 18 F-FET, 18 F-AFETP, and 18 F-FDG at the early time points were 2.9 6 0.2, 6.2 6 1, and 0.9 6 0.1, respectively, and at the late time points were 2.0 6 0.3, 7.5 6 1, and 1.3 6 0.1, respectively, as depicted in Figure 7 . The tumor-to-brain ratio achieved with 18 F-AFETP was significantly higher than with 18 F-FDG and 18 F-FET (P , 0.001 for both).
DISCUSSION
Radiochemical synthesis of 18 F-AFETP was achieved in high radiochemical purity and specific activity. Elimination of the solid-phase extraction step before HPLC during the radiolabeling process reduced the complexity of the synthesis. The larger volumes of 1 M aqueous HCl used for acidic deprotection and the use of evaporation, rather than ion-retardation chromatography, to obtain the final product in a sodium-free form increased the radiochemical purity of 18 F-AFETP, which was greater than 99%.
The cell uptake assays were performed with a short, 30-s uptake time to evaluate the initial influx of 18 F-AFETP and minimize the potential for efflux, which can be mediated by many AA transporters, including system L, system ASC, and the cationic AA transport families CAT and y 1 L. From the in vitro cell uptake assay results (Fig. 3) , the cationic AA transport substrates L-lysine and L-histidine, as well as a combination of L-arginine, L-lysine, and L-histidine, were the most effective inhibitors of 18 F-AFETP uptake. Together, these findings suggest that a significant proportion of the in vitro uptake of 18 F-AFETP is mediated by cationic AA transporters, although other AA transporters that recognize neutral AAsincluding systems A, L, and ASC-also contribute. Of note, L-arginine was a less effective inhibitor than L-lysine and L-histidine, blocking only 41% of 18 F-AFETP uptake. This result suggests that 18 F-AFETP is not an ideal surrogate for arginine transport and may be due to different selectivities for the 4 families of AA transporters (y 1 , y 1 L, b 0,1 AT, and ATB 0,1 ) that mediate most cationic AA transport. These properties may complicate the use of this tracer as a specific probe for cationic transport in vivo, and AAs with more basic side chains or other structural modifications may improve selectivity for cationic AA transporters.
The biodistribution studies with 18 F-AFETP in mice (Table 1 ) demonstrate good tumor uptake of radioactivity at 5, 30, and 60 min after injection, with higher uptake in tumor than in most normal tissues including the brain. Tumor-to-brain ratios ranged from 11:1 to 17:1, and the tumor-to-normal-tissue ratios at 30 and 60 min after injection were greater than 2:1 for the blood, bone fat, liver, muscle, and large intestine. These results are similar to prior studies using the 9 L gliosarcoma model, which demonstrated tumor-to-brain ratios of approximately 15:1 at 30 and 60 min after injection (22) . These results indicate that 18 F-AFETP tumor uptake is not cell-line-specific and may be useful for imaging tumors located in and outside the brain. The relatively low levels of activity in the bone indicate that no substantial in vivo defluorination occurred during the 60-min time course of the study. The highest levels of uptake at all time points in the study were observed in the kidneys and pancreas, a pattern frequently seen with radiolabeled AAs and similar to the biodistribution observed in the rat 9 L gliosarcoma model (22) . The relatively high levels of 18 F-AFETP in the lungs and spleen are similar to the rat biodistribution pattern but are not observed with other 18 F-labeled AA targeting system L and system A transport systems (21, 36, 37) . These differences in pulmonary and splenic uptake of activity may be related to the mechanism of transport of 18 F-AFETP, specifically the uptake via cationic AA transporters observed in vitro.
The results of small-animal PET demonstrate distinct patterns of tumor and normal brain uptake with each of the tracers evaluated. Significant differences among the uptake of 18 F-AFETP, 18 F-FDG, and 18 F-FET were observed in tumors and normal brain (Figs. 4 and 5) . Of the 3 tracers evaluated, 18 F-AFETP provided the best brain tumor visualization, although this finding was primarily due to low uptake in normal brain, as discussed in detail below. All 3 tracers demonstrated relatively high uptake in the DBTs at both early (7.5-12.5 min) and late time points (47.5-57.5 min), with 18 F-FDG significantly greater than 18 F-FET greater than 18 F-AFETP. These tracers also differed substantially in their amount of uptake in normal brain, with 18 F-FDG significantly greater than 18 F-FET greater than 18 F-AFETP. These data are shown in Figure 6 . Tumor visualization was achieved with all 3 tracers, although the uptake of 18 F-FDG in brain tumor was only slightly above that in normal brain at the conclusion of the 60-min study. As shown in Figure 7 , the tumor-to-brain ratio at the late time points achieved with 18 F-AFETP was significantly higher than with 18 F-FDG and 18 F-FET (P , 0.001 for both). There was a trend toward higher tumor-to-brain ratios with 18 F-FET than FIGURE 7 . Tumor-to-brain ratios between intracranial DBTs and contralateral normal brain measured through small-animal PET studies performed with 18 F-FET (n 5 3), 18 F-AFETP (n 5 4), and 18 F-FDG (n 5 4). Data for early (7-12.5 min) and late (47.5-57.5 min) time points are depicted. Small-animal PET data for 18 F-AFETP and 18 F-FDG were obtained in same animals, whereas 18 F-FET data were obtained in second cohort of animals. Error bars show SD. Representative time-activity curves and tumor-to-brain ratio curves observed with dynamic small-animal PET studies in mice with intracranial DBTs. Timeactivity curves for 18 F-AFETP (A), 18 F-FDG (B), and 18 F-FET (C) are displayed as average SUVs. 18 F-AFETP and 18 F-FDG data in A and B were obtained in same animal, whereas 18 F-FET data in C was from animal from different cohort. Data from time-activity curves are expressed as tumor-to-brain ratios over time for all 3 tracers in D. Figure 6 shows average data from these small-animal PET studies from all animals (n 5 3 or 4) for each tracer.
with 18 F-FDG, but this did not reach statistical significance; this result may be due, in part, to less normal brain 18 F-FDG uptake because of the isoflurane anesthesia. The tumor-to-brain ratios observed with 18 F-AFETP in the small-animal PET studies were somewhat lower than those observed in the biodistribution studies, which may be due to partial-volume averaging in the brain tumors. Also, the tumor-to-brain ratios were constant in the small-animal PET studies using 18 F-AFETP but decreased at the 60-min time point in the biodistribution study. The reason for this difference is unclear but could be due to anesthesia effects on intracranial blood flow or AA transporter activity because the small-animal PET studies were conducted under anesthesia throughout the imaging period whereas the animals were anesthetized only during tracer injection for the biodistribution studies.
The relatively low normal brain uptake of 18 F-AFETP in the mouse DBT model warrants further consideration, because it provides both potential advantages and potential disadvantages for this tracer. The low brain uptake is a major factor in the higher tumor-tobrain ratios observed with 18 F-AFETP than with 18 F-FET and 18 F-FDG. Higher tumor-to-normal-tissue ratios can provide better tumor visualization and a larger dynamic range for assessing response to therapy. However, most low-grade tumors do not have grossly disrupted BBBs, and many high-grade gliomas, including glioblastoma, have nonenhancing regions not readily assessed with conventional contrast-enhanced MR imaging. One of the primary strengths of system L substrates such as 18 F-FET is their ability to cross the BBB and image the nonenhancing regions of gliomas more effectively than conventional MR imaging or 18 F-FDG (3, 6, 8, 36) . The low brain uptake of 18 F-AFETP is somewhat unexpected, because cationic AAs can cross the BBB via the CAT-1 transporter (38) , and 14 C-labeled L-histidine demonstrated uptake similar to 14 Clabeled methionine, tyrosine, and 3,4-dihydroxyphenylalanine in rat brain after intraarterial injection into the carotid artery (39) . The reason for the low brain uptake in our studies is unclear, but possible mechanisms include competition from endogenous AAs, lack of transport by CAT-1, and efflux transporters that mediate the clearance of 18 F-AFETP from the brain.
CONCLUSION
The nonnatural AA 18 F-AFETP has good tumor imaging properties in the mouse DBT model of glioblastoma, with rapid and persistent tumor uptake. High tumor-to-brain, tumor-to-muscle, and tumor-to-blood ratios were observed at 30 and 60 min after injection, with higher tumor-to-brain ratios than obtained with 18 F-FET or 18 F-FDG. In vitro assays demonstrate that the uptake of this tracer is mediated, in part, by cationic AA transporters. The relatively low brain uptake may limit visualization of nonenhancing gliomas, and ongoing work is aimed at developing analogs with greater brain availability and higher selectivity for cationic AA transport.
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